How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
PCI Synthesis - API Manufacturing Capabilities
Do's and Don'ts of API Technology Transfer in Phases 1, 2 and 3 Clinical Trials
Sound Process Optimization Never Really Ends
Are You Implementing a “Right-First-Time” Approach to Synthetic Route Selection for APIs?
New Automated Purification Strategies for Scale-Up
About the Author
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).